An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

Figures & data

Table 1 FDA-approved indications for pantoprazole in the treatment of gastroesophageal reflux disease (GERD) in the US

Year	Indication	Dosage	Route	Duration
2000	Healing of erosive esophagitis	40 mg daily	po capsule	8–16 weeks
2000	Maintenance of erosive esophagitis	40 mg daily	po capsule	Continuous
2001	Erosive esophagitis with GERD unable to tolerate po	40 mg daily	iv	7–10 days
2007	Erosive esophagitis with GERD unable to tolerate po capsule	40 mg daily	po suspension	Continuous

Abbreviations: FAD, US Food and Drug Administration; iv, intravenous; po, by mouth.